Literature DB >> 8103774

Comparison of typing methods for Clostridium difficile isolates.

M J Wolfhagen1, A C Fluit, R Torensma, M Jansze, A F Kuypers, E A Verhage, J Verhoef.   

Abstract

A simple discriminative typing method for Clostridium difficile has been developed. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of whole-cell proteins and restriction enzyme analysis are relatively simple techniques but are difficult to evaluate, especially the restriction enzyme analysis. Immunoblotting and restriction fragment length polymorphism typing facilitate simple discrimination of patterns.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8103774      PMCID: PMC265725          DOI: 10.1128/jcm.31.8.2208-2211.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  8 in total

1.  Non-radioactive restriction fragment length polymorphism (RFLP) typing of Clostridium difficile.

Authors:  R A Bowman; G L O'Neill; T V Riley
Journal:  FEMS Microbiol Lett       Date:  1991-04-15       Impact factor: 2.742

2.  Nosocomial Clostridium difficile colonisation and disease.

Authors:  S Johnson; C R Clabots; F V Linn; M M Olson; L R Peterson; D N Gerding
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

3.  Broad range DNA probes for detecting and amplifying eubacterial nucleic acids.

Authors:  K Chen; H Neimark; P Rumore; C R Steinman
Journal:  FEMS Microbiol Lett       Date:  1989-01-01       Impact factor: 2.742

4.  Comparison of serogrouping and polyacrylamide gel electrophoresis for typing Clostridium difficile.

Authors:  M Delmée; Y Laroche; V Avesani; G Cornelis
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

5.  Typing of Clostridium difficile causing diarrhoea in an orthopaedic ward.

Authors:  I McKay; J E Coia; I R Poxton
Journal:  J Clin Pathol       Date:  1989-05       Impact factor: 3.411

6.  Typing scheme for Clostridium difficile: its application in clinical and epidemiological studies.

Authors:  S Tabaqchali; D Holland; S O'Farrell; R Silman
Journal:  Lancet       Date:  1984-04-28       Impact factor: 79.321

7.  Postantibiotic colonization with Clostridium difficile in nursing home patients.

Authors:  D R Thomas; R G Bennett; B E Laughon; W B Greenough; J G Bartlett
Journal:  J Am Geriatr Soc       Date:  1990-04       Impact factor: 5.562

Review 8.  Antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett
Journal:  Rev Infect Dis       Date:  1979 May-Jun
  8 in total
  6 in total

1.  Rapid identification of bacteria by PCR-single-strand conformation polymorphism.

Authors:  M N Widjojoatmodjo; A C Fluit; J Verhoef
Journal:  J Clin Microbiol       Date:  1994-12       Impact factor: 5.948

2.  Comparison of restriction enzyme analysis, arbitrarily primed PCR, and protein profile analysis typing for epidemiologic investigation of an ongoing Clostridium difficile outbreak.

Authors:  M E Rafferty; A L Baltch; R P Smith; L H Bopp; C Rheal; F C Tenover; G E Killgore; D M Lyerly; T D Wilkins; D J Schoonmaker; G E Hannett; M Shayegani
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

3.  Genotyping of outbreak-related and sporadic isolates of Clostridium difficile belonging to serogroup C.

Authors:  P van Dijck; V Avesani; M Delmée
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

4.  Phospholipid profiles of Clostridium difficile.

Authors:  D B Drucker; H M Wardle; V Boote
Journal:  J Bacteriol       Date:  1996-10       Impact factor: 3.490

5.  Rapid detection of toxigenic Clostridium difficile in fecal samples by magnetic immuno PCR assay.

Authors:  M J Wolfhagen; A C Fluit; R Torensma; M J Poppelier; J Verhoef
Journal:  J Clin Microbiol       Date:  1994-07       Impact factor: 5.948

6.  Clinical significance of Clostridium difficile and its toxins in faeces of immunocompromised children.

Authors:  M J Wolfhagen; K Meijer; A C Fluit; R Torensma; R A Bruinsma; A Fleer; J Verhoef
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.